FDA-approved1,3,4,5Evidence: Large human trialsMetabolic and weight

Liraglutide1

Also called Saxenda, Victoza2,3

Key takeaway

Liraglutide is a lab-made version of the gut hormone GLP-1. Drugs@FDA lists it as the active ingredient of Victoza, first approved in 2010, and Saxenda, first approved in 2014, and FDA has since approved generic versions.1,3,4,5 The liraglutide weight-management label cited here covers long-term weight reduction in adults, and in children aged 12 and older with obesity and body weight above 60 kilograms.1 Large randomized trials support it, including three 56-week weight trials described in the label and the LEADER cardiovascular outcomes trial of 9,340 adults with type 2 diabetes.1,7 The label carries a boxed warning about thyroid C-cell tumors seen in rats and mice; whether liraglutide causes them in humans is unknown.1

Liraglutide at a glance

What it isA GLP-1 receptor agonist. The label describes it as an acylated human GLP-1 receptor agonist with 97% amino acid sequence similarity to natural human GLP-1.1
FDA statusFDA-approved. Drugs@FDA lists Victoza (first approved January 25, 2010), Saxenda (December 23, 2014) and generic liraglutide applications, the first approved December 23, 2024. The label carries a boxed warning about thyroid C-cell tumors in rodents.1,3,4,5
Human evidenceLarge randomized, placebo-controlled trials: weight trials described in the label and the published LEADER cardiovascular outcomes trial.1,7
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is liraglutide?

Liraglutide is a lab-made peptide modeled on GLP-1, a hormone released by the gut. The label describes it as an acylated human GLP-1 receptor agonist with 97% amino acid sequence similarity to natural human GLP-1.1

Drugs@FDA lists two Novo Nordisk brands, Victoza and Saxenda, and approved generic applications from other companies.3,4,5

How does liraglutide work?

The label states that liraglutide binds to and activates the GLP-1 receptor, like the natural hormone, and that GLP-1 is a physiological regulator of appetite and calorie intake.1

According to the label, natural GLP-1 is broken down within minutes, while liraglutide resists that breakdown and lasts much longer in the body. In rats, it activated brain regions that regulate appetite, though the label says the specific regions behind its effect on appetite were not identified.1

What do human studies show?

The label describes three 56-week randomized, placebo-controlled weight trials. In the largest, of 3,731 adults without type 2 diabetes, average weight fell 7.4% with liraglutide and 3% with placebo, and 62.3% and 34.4%, respectively, lost at least 5% of their body weight.1

In the 56-week trials, the label reports that 27% of the liraglutide groups and 35% of the placebo groups stopped the study drug, and about 10% and 4%, respectively, stopped because of an adverse reaction.1

In LEADER, 9,340 adults with type 2 diabetes and high cardiovascular risk were followed for a median of 3.8 years. The main cardiovascular outcome occurred in 13.0% of the liraglutide group and 14.9% of the placebo group, a reported hazard ratio of 0.87.7

LEADER was funded by its sponsor, and its findings apply to adults with type 2 diabetes at high cardiovascular risk who were receiving standard care.7

What the evidence base contains

  • Large randomized human trial A 56-week randomized, double-blind, placebo-controlled weight trial in 3,731 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes.1
  • Large randomized human trial A 56-week randomized, double-blind, placebo-controlled weight trial in 635 adults with type 2 diabetes and overweight or obesity.1
  • Large randomized human trial LEADER, a double-blind, randomized, placebo-controlled cardiovascular outcomes trial in 9,340 adults with type 2 diabetes and high cardiovascular risk, published in The New England Journal of Medicine.7
  • Controlled human trial A 56-week randomized, double-blind, placebo-controlled trial in 251 adolescents aged 12 to 17 with obesity (NCT02918279).1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is liraglutide FDA-approved?

Yes. Drugs@FDA records list Victoza’s original approval on January 25, 2010 and Saxenda’s on December 23, 2014. Generic liraglutide applications have also been approved, the first on December 23, 2024.3,4,5

The label cited here, for a generic liraglutide weight-management product (DailyMed SPL version 6, published July 14, 2026), states that it is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults and children aged 12 and older with obesity and body weight above 60 kilograms, and in adults with overweight and at least one weight-related condition.1

The label states that safety and effectiveness in children with type 2 diabetes have not been established. Uses of other liraglutide products, such as Victoza, are set by their own labels, which are not cited here.1

The label carries a boxed warning: liraglutide caused thyroid C-cell tumors in rats and mice, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. The label states that it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1

Other warnings in the label cover acute pancreatitis, gallbladder disease, low blood sugar, increased heart rate, kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions and aspiration during anesthesia or deep sedation.1

In January 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove a warning about suicidal thoughts and behavior from their labels, after its review found no increased risk with GLP-1 medicines. The label cited here lists that warning as removed in February 2026.1,2

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities, saying it found no clinical need for them to compound these drugs from bulk substances. FDA invited comments through June 29, 2026.6

Timeline

  1. FDA approves Victoza, the first liraglutide product, according to Drugs@FDA.3
  2. FDA approves Saxenda, according to Drugs@FDA.4
  3. LEADER cardiovascular outcomes results are published.7
  4. FDA approves the first generic liraglutide application in the records cited here.5
  5. FDA asks the makers of Saxenda, Wegovy and Zepbound to remove a suicidal thoughts and behavior warning from their labels.2
  6. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.6
  7. DailyMed publishes the liraglutide label version cited on this page.1

What is still unknown?

Whether liraglutide causes thyroid C-cell tumors in humans, which the label says has not been determined.1

Whether LEADER’s cardiovascular result applies to people at lower cardiovascular risk or without type 2 diabetes, who were not studied in that trial.7

How benefits and harms change after treatment stops and over longer follow-up than the trials reviewed here.7

Whether FDA will finalize its April 2026 proposal on the 503B bulks list, which remained a proposal in the sources reviewed through November 14, 2026.6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Liraglutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Liraglutide are the records PeptideScanner has selected and published, not every registration or paper about Liraglutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Victoza, Saxenda and generic versions. The cited generic weight-management label covers adults and children aged 12 and older with obesity, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA proposed in April 2026 to exclude liraglutide from the 503B bulks list.↗↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed August 19, 2026 · Review version 1.

Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.

A bounded review of two sponsor-funded randomized trials: one 56-week weight-management trial and one cardiovascular-outcomes trial in type 2 diabetes.↗↗

What the reviewed sources report

The reviewed weight-management trial reported greater mean weight reduction than placebo, and the reviewed cardiovascular trial reported fewer primary cardiovascular events in a high-risk type 2 diabetes population. The findings remain specific to the studied populations and trial conditions.↗↗

What remains unresolved?

  • How do benefits and harms vary in lower-risk populations, after discontinuation, and over follow-up beyond the reviewed trials?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Liraglutide injection for weight management · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The cited generic injection label covers long-term weight reduction alongside diet and activity in adults with obesity or overweight with a weight-related condition, and children aged twelve years and older with obesity and body weight above 60 kg. It does not establish the scope of every liraglutide product. Label: 1 ↗

Which safety limits matter?

The boxed warning reports thyroid C-cell tumors in rodents, with uncertain human relevance. Contraindications include personal or family medullary thyroid carcinoma, MEN 2 and hypersensitivity. Other warnings address pancreatitis, gallbladder disease, hypoglycemia, increased heart rate, kidney injury from volume depletion, severe gastrointestinal reactions and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

Liraglutide injection, solution · SPL version 6 · published 2026-07-14

Label ZIP SHA-256: 48d493b4dc6af7d7574aedf0a2f7ab6235a9ed62875baffe6c484b5433647541. Extracted XML SHA-256: 26e94f7191fa24c8a25945ac1cd23ef4a95e897a8c9e84520043a4d7ff6edbef.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Liraglutide?

Manually reviewed August 19, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of two sponsor-funded randomized trials: one 56-week weight-management trial and one cardiovascular-outcomes trial in type 2 diabetes.12

Bottom line from this bounded source set

The reviewed weight-management trial reported greater mean weight reduction than placebo, and the reviewed cardiovascular trial reported fewer primary cardiovascular events in a high-risk type 2 diabetes population. The findings remain specific to the studied populations and trial conditions.12

Reviewed study record

SCALE weight-management trial

Design

A double-blind, randomized, placebo-controlled trial assessed body-weight change over 56 weeks alongside lifestyle counseling.1

Population

The trial randomized 3,731 adults without type 2 diabetes who had obesity, or overweight with dyslipidemia or hypertension.1

Outcomes reported

Reported mean weight loss was 8.4 kilograms with liraglutide and 2.8 kilograms with placebo. At least 5% weight loss was reported for 63.2% and 27.1%, respectively, and gastrointestinal events were common.1

Limitations

The sponsor-funded trial combined treatment with lifestyle counseling, excluded type 2 diabetes, and used imputation for the reported mean weight-change analysis.1

Reviewed study record

LEADER cardiovascular-outcomes trial

Design

A double-blind, randomized, placebo-controlled cardiovascular-outcomes trial followed participants for a median of 3.8 years.2

Population

The trial randomized 9,340 adults with type 2 diabetes and high cardiovascular risk in addition to standard care.2

Outcomes reported

The primary composite cardiovascular outcome occurred in 13.0% of the liraglutide group and 14.9% of the placebo group, with a reported hazard ratio of 0.87. Gastrointestinal events were the most common events leading to discontinuation.2

Limitations

The sponsor-funded findings apply to a high-cardiovascular-risk type 2 diabetes population receiving standard care and do not establish the same effect in lower-risk populations.2

Reviewed source set

  1. PubMed · 26132939A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management ↗PubMed PMID 26132939 · EFetch XML reviewed 2026-08-19 · payload SHA-256 5c94f293c86af2a279cfa8ae529f06100cf2dce79b2009b0a6ba26fb9ca9bce6
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1411892. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 27295427Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes ↗PubMed PMID 27295427 · EFetch XML reviewed 2026-08-19 · payload SHA-256 d86dca944a90d406ed7a98e6e46eb8d9774504c7746b167351df04f923325e26
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1603827. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The initial glycemic trials and later outcomes trial answer different questions

EMA’s 2009 assessment primarily evaluated glucose control with specific background therapies and comparators. The later LEADER assessment directly evaluated cardiovascular events in a high-risk type 2 diabetes population. EMA PDF pp. 45 ↗EMA PDF pp. 78 ↗

More findings, study links and document coverage

LEADER measured clinical cardiovascular events

The 9,340-participant randomized trial added liraglutide or placebo to standard care. Over median observation of 3.84 years, first major cardiovascular events occurred in 13.0% versus 14.9%; the hazard ratio was 0.87 (95% CI 0.78–0.97). EMA PDF pp. 78 ↗

Do not generalize the high-risk population to everyone

EMA considered the principal endpoint reliable but cautioned about exploratory findings. Results in people with risk factors alone were less consistent; the study did not establish an unrestricted first-line treatment claim for newly diagnosed diabetes. EMA PDF pp. 84, 85, 87 ↗

A composite kidney result is not every kidney outcome

The exploratory nephropathy result was mainly driven by new macroalbuminuria. No differences were found for renal replacement therapy or doubling of creatinine in that analysis; these components should not be presented as equivalent findings. EMA PDF pp. 79 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Matched study identities

Protocol identifiers were matched to ClinicalTrials.gov records. This does not count extensions as new independent trials.

Document coverage

Selected sections read in 2 of 35 inventoried documents; 33 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

Remaining work

  • Appraise Saxenda weight-management and pediatric documents separately from the Victoza diabetes program.
  • Complete the remaining variation, safety and study-level readings in the candidate inventory.

Open versioned document coverage and study pins →

European medicine records · 5 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

5625 retrieved · 2 included · 0 excluded · 5623 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Liraglutide"[Title/Abstract] OR "Saxenda"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:36.495785+00:00 · HTTP 200 · SHA-256 1cfce35fa93d082bb580f40b718ff2704d5677380309e20a8be7757e5928004d.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.

Showing 25 of 5625 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 27295427 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01179048.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 d86dca944a90d406ed7a98e6e46eb8d9774504c7746b167351df04f923325e26.

  2. PubMed 26132939 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01272219.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 5c94f293c86af2a279cfa8ae529f06100cf2dce79b2009b0a6ba26fb9ca9bce6.

  3. PubMed 42737442 — not screened: Name-query match awaiting clinical eligibility screening.
  4. PubMed 42736522 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42736040 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42736027 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42732089 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42727920 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42726083 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42725235 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42723821 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42723672 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42718598 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42708757 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42697206 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42695487 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42695140 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42693519 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42692655 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 42692477 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42692277 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42692107 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42687799 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

14 retrieved · 14 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"LIRAGLUTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:19.744283+00:00 · HTTP 200 · SHA-256 18a2acd6a79a9dbd68ed860f7cb4c15c66227e6e8f5992f91aa507e78ee76d04.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 14 of 14 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA206321 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  2. FDA ANDA215503 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  3. FDA BLA208583 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: INSULIN DEGLUDEC, LIRAGLUTIDE.
  4. FDA ANDA217234 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  5. FDA ANDA218115 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  6. FDA ANDA213155 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  7. FDA ANDA215245 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  8. FDA ANDA212552 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  9. FDA NDA022341 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  10. FDA ANDA217063 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  11. FDA ANDA212972 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  12. FDA ANDA214568 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  13. FDA ANDA215421 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.
  14. FDA ANDA217590 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIRAGLUTIDE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

5 retrieved · 5 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Liraglutide", "Saxenda"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/006620 — include: EMA feed product Ablymico; reported status: Authorised. Exact indication and decision documents remain unappraised.
  2. EMA EMEA/H/C/006615 — include: EMA feed product Liraglutide STADA; reported status: Authorised. Exact indication and decision documents remain unappraised.
  3. EMA EMEA/H/C/001026 — include: EMA feed product Victoza; reported status: Authorised. Exact indication and decision documents remain unappraised.
  4. EMA EMEA/H/C/003780 — include: EMA feed product Saxenda; reported status: Authorised. Exact indication and decision documents remain unappraised.
  5. EMA EMEA/H/C/002647 — include: EMA feed product Xultophy; reported status: Authorised. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

79 retrieved · 55 included · 0 excluded · 24 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Liraglutide", "Saxenda"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 25 of 79 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 5631 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - Public assessment report
  2. EMA 8772 — include: Document linked by EMA product number; content unappraised. Xultophy-H-C-2647-II-0002 : EPAR - Assessment Report - Variation
  3. EMA 8989 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-PSUSA-00001892-201512 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  4. EMA 10275 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Assessment Report - Variation
  5. EMA 11269 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - Medicine overview
  6. EMA 12669 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0005-G : EPAR - Assessment Report - Variation
  7. EMA 13799 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-3780-P46-017 : EPAR - Assessment Report
  8. EMA 19530 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - All Authorised presentations
  9. EMA 21017 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-PSUV-0029 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
  10. EMA 21758 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0042 : EPAR - Assessment Report - Variation
  11. EMA 22634 — include: Document linked by EMA product number; content unappraised. Xultophy-H-C-PSUSA-00010272-201603 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  12. EMA 29678 — include: Document linked by EMA product number; content unappraised. Xultophy-PSUSA-00010272-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  13. EMA 32913 — include: Document linked by EMA product number; content unappraised. Xultophy : EPAR - Risk-management-plan summary
  14. EMA 34192 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Medicine overview
  15. EMA 35801 — include: Document linked by EMA product number; content unappraised. Xultophy-H-C-002647-II-0023 : EPAR - Assessment Report - Variation
  16. EMA 36093 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-P46-0029 : EPAR - Assessment Report
  17. EMA 36517 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Public assessment report
  18. EMA 36966 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - All Authorised presentations
  19. EMA 37786 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-PSUSA-00001892- 201512: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
  20. EMA 38842 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-3780-P46-016 : EPAR - Assessment Report
  21. EMA 40021 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0023: EPAR - Assessment Report - Variation
  22. EMA 45716 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-1026-II-0049: EPAR - Assessment Report - Variation
  23. EMA 45717 — include: Document linked by EMA product number; content unappraised. Victoza : EPAR - Risk-management-plan summary
  24. EMA 45897 — include: Document linked by EMA product number; content unappraised. Saxenda-H-C-PSUSA-00001892-201812 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  25. EMA 45901 — include: Document linked by EMA product number; content unappraised. Victoza-H-C-PSUSA-00001892- 201812: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Liraglutide", "Saxenda"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EU/3/22/2667 — include: EMA orphan feed identifies liraglutide; designation status: Positive. Orphan designation is not marketing authorization.

ClinicalTrials.gov search

ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

546 retrieved · 0 included · 0 excluded · 546 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Liraglutide" OR "Saxenda" OR "Ablymico" OR "Liraglutide STADA" OR "Victoza" OR "Xultophy"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:28.806470+00:00 · HTTP 200 · SHA-256 7c583f99a9a1fa2f59c5726b7ae8c94b6d5384bc2e95251e9666c4ab0e11bc56.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:30.145596+00:00 · HTTP 200 · SHA-256 a81c85265b3fda5ba360a2e5987f049db1de25a8982fe163252c318386f6274b.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:31.696378+00:00 · HTTP 200 · SHA-256 4617322e80e0498413054690483e80a8106e71079eb5bf0846eea6927779075f.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:33.239312+00:00 · HTTP 200 · SHA-256 1ced2233ada1294daa41e84de551bf739649d69b65fdb02ef51f7208abd95667.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:34.793608+00:00 · HTTP 200 · SHA-256 b2f941379006d3144d3b02558c4992229f849dda0402eee4309ebaa7741d35a4.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:26:36.160792+00:00 · HTTP 200 · SHA-256 6a792f095eebae791bcb967e55a94748ec56cf115d43ba7467b7f06767b0f66f.

  • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
  • Other registries, unregistered studies and additional aliases remain outside this query.

Showing 25 of 546 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT01595789 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  2. ClinicalTrials.gov NCT01507285 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  3. ClinicalTrials.gov NCT02292290 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  4. ClinicalTrials.gov NCT05479591 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  5. ClinicalTrials.gov NCT01288326 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  6. ClinicalTrials.gov NCT01800968 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  7. ClinicalTrials.gov NCT02863419 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  8. ClinicalTrials.gov NCT02140983 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  9. ClinicalTrials.gov NCT03885297 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  10. ClinicalTrials.gov NCT01508923 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  11. ClinicalTrials.gov NCT00700817 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  12. ClinicalTrials.gov NCT05225974 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  13. ClinicalTrials.gov NCT01845259 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  14. ClinicalTrials.gov NCT01602913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  15. ClinicalTrials.gov NCT01592279 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  16. ClinicalTrials.gov NCT02777073 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  17. ClinicalTrials.gov NCT03260881 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  18. ClinicalTrials.gov NCT03101930 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  19. ClinicalTrials.gov NCT03555994 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  20. ClinicalTrials.gov NCT01509742 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  21. ClinicalTrials.gov NCT02016846 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  22. ClinicalTrials.gov NCT04034524 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  23. ClinicalTrials.gov NCT05812183 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  24. ClinicalTrials.gov NCT01934816 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
  25. ClinicalTrials.gov NCT01677104 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Liraglutide?

FDA-approved as Victoza, Saxenda and generic versions. The cited generic weight-management label covers adults and children aged 12 and older with obesity, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA proposed in April 2026 to exclude liraglutide from the 503B bulks list.↗↗↗↗↗

The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
4
Source years
17
Drugs@FDA applications
13

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Liraglutide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

173Selected dated records
175Connected citations
17Populated source years2009–2026
4/4Record lanes present

Registered human studies

Trial composition

18 of 82 selected trial records include at least one phase value; 19 of 82 include a status value in the retained structured contract.

820 public history versions connect to 77 of these trial records across 21 submitted years. Open the record-history collection →

PhasesPhase 4 8Phase 3 4Not applicable 2Phase 1 2Phase 2 2
Status at observationCompleted 14Recruiting 3Active, not recruiting 2

A phase value is unavailable here for 64 selected records; this is not counted as “no phase.”

A status value is unavailable here for 63 selected records; this is not counted as a trial status.

PubMed bibliography

Publication composition

29 of 58 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 21Letter 8Case Reports 7Research Support, Non-U.S. Gov't 6Review 4English Abstract 2Multicenter Study 2Randomized Controlled Trial 2Clinical Trial 1Comment 1Comparative Study 1

Bibliography fields unavailable here for 29 selected records; the records remain visible as metadata observations.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
13
FDA Federal Register documents
13
DailyMed SPL versions
2
Canonical profile
Published
Profile structured data
Published
Linked dated records
173

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 173 dated records

Research hub

Explore the Liraglutide evidence record

Open all 173 records →
173Dated records
4Evidence types
173Cited public sources
17Source years

Change ledger

Recently changed for Liraglutide

Open all 178 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record updated

ClinicalTrials.gov record NCT04775082

ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Record updated

Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.

PubMed revised the bibliographic metadata of PMID 42708757, with a metadata revision date of 2026-09-11. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
September 11, 2026
Evidence lane
Literature metadata
Profile status changed

Liraglutide profile

We added a plain-language reader guide with cited answers, re-checked the liraglutide label and the Drugs@FDA approval records, and added the LEADER trial report and FDA’s April 2026 503B proposal.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Official-source collections

Source records for Liraglutide

Open the full research atlas →
PubMed58

29 with attributed title, venue, publication-date, and type metadata.

  1. Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.Cardiovascular drugs and therapy · 2026 10 17
  2. Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.Analytical chemistry · 2026 Sep 08
  3. Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.Endocrinology, diabetes & metabolism · 2026 Sep
Explore all selected literature →
ClinicalTrials.gov82

820 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT04775082Registry update November 16, 2026 · current at observation
  2. NCT07913685Registry update November 3, 2026 · completed at observation
  3. NCT04466566Registry update October 28, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA13

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA212972Full FDA chronology · original submission status AP 2026-07-01
  2. ANDA213155Full FDA chronology · original submission status AP 2026-06-15
  3. ANDA212552Full FDA chronology · original submission status AP 2026-03-30
  4. ANDA215245Full FDA chronology · original submission status AP 2026-03-11
  5. ANDA217063Full FDA chronology · original submission status AP 2026-02-24
Explore all selected FDA applications →Explore 61 dated submissions and 94 documents for Liraglutide →
FDA enforcement reports3

Recall-enforcement metadata connected only through exact application numbers already mapped to this reviewed profile.

  1. D-0541-2026Class II · report date 2026-05-27
  2. D-0618-2021Class II · report date 2021-04-21
  3. D-0622-2021Class II · report date 2021-04-21
Explore all exact FDA enforcement reports →

Evidence types

Coverage by source year

Selected records span March 10, 2009 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration3,6
Dated updates connected to this profile · 173

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT04775082↗

    PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT07913685↗

    PeptideScanner retained ClinicalTrials.gov record NCT07913685 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was liraglutide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04466566↗

    PeptideScanner retained ClinicalTrials.gov record NCT04466566 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was liraglutide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06976619↗

    PeptideScanner retained ClinicalTrials.gov record NCT06976619 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was liraglutide.↗

  5. Literature metadata

    Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.↗

    PubMed lists PMID 42891862 in Cardiovascular drugs and therapy as Letter, with publication-date metadata of 2026-10-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.↗

    PubMed lists PMID 42762462 in Endocrinology, diabetes & metabolism as Journal Article, Multicenter Study, with publication-date metadata of 2026-09 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.↗

    PubMed lists PMID 42723672 in F1000Research as Journal Article, Review, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.↗

    PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Treatment of obesity with liraglutide in bipolar disorder: a case report.↗

    PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study.↗

    PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT03883412↗

    PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.↗

  12. Literature metadata

    PubMed record PMID 38240127↗

    PeptideScanner retained PubMed bibliographic metadata for PMID 38240127 at 2026-08-10T10:49:06.873Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2024-01-19. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  3. 3
    Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  7. 7
    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER, 2016) · PMID 27295427 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026